Imagion Biosystems Updates Capital Raise to $2.5 Million
Imagion Biosystems Limited previously advised that the Renounceable Rights Issue announced on 25 March 2020 ("Offer") has closed oversubscribed and raised…
Second Supplementary Prospectus
Imagion Biosystems has announced a Secondary Supplementary Prospectus. Read the Secondary Supplementary Prospectus.
Proposed Issue of Securities
Imagion Biosystems has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.
Imagion Biosystems Trading Halt
The securities of Imagion Biosystems Limited ('IBX') will be placed in a trading halt at the request of IBX, pending it releasing an announcement. Unless ASX…
Imagion Rights Issue Oversubscribed Raising $3 Million
Imagion Biosystems Limited is pleased to advise that the Renounceable Rights Issue announced on 25 March 2020 ("Offer") has closed oversubscribed and raised…
Supplementary Prospectus
A supplementary prospectus has been lodged with the Australian Securities and Investments Commission. This supplementary prospectus is intended to be read with…
Quarterly Cashflow Report – Period Ending 31 March 2020
Imagion Biosystems has today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 31 March 2020. Read the…
Imagion Biosystems Receives A$2.2 Million in R&D Tax Incentives
Imagion Biosystems has announced receipt of its 2019 R&D tax incentive claim of A$2,197,028 from the Australian Tax Office (ATO). In May 2019 the…
Bob Proulx Discusses the Opportunity for MagSense™ Imaging
Watch Imagion CEO Bob Proulx discuss the opportunity for MagSense™ Imaging on Switzer's CEO Masterclass: https://youtu.be/kpJ0Lpwdk38 Today’s imaging…
Rights Trading Commences
Imagion Biosystems Limited (ASX:IBX) is pleased to confirm that the rights the subject of the Company’s Renounceable Rights Issue announced on Wednesday, 25…